Breast Cancer Excellence Forum

Breast Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Videos

Optimizing Treatment for Patients With High-Risk HER2-Positive Breast Cancer

02/21/2024

Featuring Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Featuring Reshma Mahtani, DO; Terry M...

In this video, our experts explore therapy options for patients with high-risk HER2-positive breast cancer, sharing their views on anthracycline-based therapies, neratinib, and immunotherapy for these patients, and discussing data from the...

In this video, our experts...

02/21/2024

Oncology

Videos

Managing Patients With Stage 1 HER2-Positive Breast Cancer

02/21/2024

Featuring Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Featuring Reshma Mahtani, DO; Terry M...

In this video, a panel of experts discuss the management of patients with stage 1, HER2-positive breast cancer, sharing data from several trials in this space, including the APT, ADEPT, and ATEMPT 2.0 trials.

In this video, a panel of...

02/21/2024

Oncology

Videos

Neoadjuvant vs Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer

02/15/2024

In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...

In this video, a panel of...

02/15/2024

Oncology

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Videos

Considerations for Endocrine Therapy for Patients With ER-Positive Early Breast Cancer

12/12/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 4 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for endocrine therapy for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 4 of...

12/12/2023

Oncology

Videos

Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer

12/12/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 3 of...

12/12/2023

Oncology

Videos

Response to Short Preoperative Endocrine Therapy Among Patients With HR-Positive, HER2-Negative Breast Cancer

12/08/2023

Featuring Oleg Gluz, MD

Oleg Gluz, MD, shares results from the screening cohort of the phase 3 ADAPTcycle trial.

Oleg Gluz, MD, shares results...

12/08/2023

Oncology

Peter Schmid, MD, PhD, Barts Cancer Center

Videos

Addition of Pembrolizumab to Neoadjuvant Chemotherapy Plus Adjuvant Pembrolizumab Improved EFS Among Patients with Early-Stage Triple-Negative Breast Cancer

12/08/2023

Featuring Peter Schmid, MD, PhD

Featuring Peter Schmid, MD, PhD ...

Peter Schmid, MD, PhD, presents updated results from the KEYNOTE-522 study, describing the benefit of adding pembrolizumab to neoadjuvant chemotherapy with adjuvant pembrolizumab in early-stage triple-negative breast cancer.

Peter Schmid, MD, PhD, presents...

12/08/2023

Oncology

Michail Ignatiadis, MD, PhD, Jules Bordet Institute

Videos

No Benefit From Addition of Atezolizumab to Adjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer

12/07/2023

Featuring Michail Ignatiadis, MD, PhD

Featuring Michail Ignatiadis, MD, PhD...

Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.

Michail Ignatiadis, MD, PhD,...

12/07/2023

Oncology

Videos

Selecting CDK4/6 Inhibitors for Patients With ER-Positive Early Breast Cancer

12/07/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 2 of...

12/07/2023

Oncology

Sara Hurvitz, MD, Fred Hutchinson Cancer Center

Videos

Tucatinib Plus Trastuzumab Emtansine Improved Progression-Free Survival Among Patients With HER2-Positive Metastatic Breast Cancer

12/06/2023

Featuring Sara Hurvitz, MD

Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.

Sara Hurvitz, MD, shares results...

12/06/2023

Oncology

Recent News

News

National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer

09/29/2021

Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.

Findings from a national...

09/29/2021

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology